AI technology has been revolutionising various sectors, with healthcare being a significant area witnessing transformative changes. As artificial intelligence continues to integrate into healthcare systems, its role in end-of-life care has become a topic of considerable debate and concern, especially regarding ethical implications. AI's ability to manage and automate aspects of advance care directives raises questions about the preservation of patient autonomy and the potential for AI-driven tools to influence critical healthcare decisions.
Advance care directives are essential legal documents that outline a patient's preferences for medical treatment in scenarios where they may not be able to communicate their wishes directly. Traditionally, these directives have been managed through written documents. However, the introduction of AI into this process comes with both opportunities and risks. AI systems can streamline the creation and management of these directives but could inadvertently lead patients towards choices they might not genuinely desire without adequate safeguards.
A vivid example of human-centred approaches in this domain is the MIDEO (My Informed Decision on VidEO) system, pioneered by Dr. Ferdinando Mirarchi. This innovative tool serves as a video-based advance care plan, allowing patients to articulate their healthcare preferences in a more personalised and comprehensible manner. Dr. Mirarchi, who is the Chief Executive Officer and Chief Medical Officer at USACS MIDEO, LLC, has critically contributed to addressing the complexities surrounding advance directives.
Dr. Mirarchi's leadership extends beyond his role at USACS MIDEO. Recently appointed Chair of the National Palliative Care Committee for US Acute Care Solutions (USACS), he has been instrumental in conducting the TRIAD Research Series (The Realistic Interpretation of Advance Directives). This research has highlighted a critical patient safety risk stemming from misunderstandings related to living wills, Do Not Resuscitate (DNR) orders, and Physician Orders for Life-Sustaining Treatment (POLST). The TRIAD findings have played a crucial role in creating evidence-based safety solutions like MIDEO, aiming for clarity and rapid access to patient directives.
His contributions have been widely recognised across reputable platforms, including the New York Times and the Washington Post. Dr. Mirarchi’s expertise is further acknowledged through his involvement with notable scientific journals such as CHEST and the Journal of the American Geriatrics Society (JAGS), and his role on the Editorial Board of Patient Safety Magazine.
Dr. Mirarchi's extensive experience is underscored by his past positions, notably as the Medical Director of the University of Pittsburgh Medical Center (UPMC) Hamot Emergency Department in Erie, Pennsylvania, and as Chief of Emergency Services for UPMC’s Northern Tier.
In conclusion, while AI continues to make strides in healthcare by enhancing operational efficiencies and decision-making processes, ethical considerations remain crucial, particularly in end-of-life care. Solutions like MIDEO, focused on patient autonomy and clear communication, are essential counterbalances to the technological momentum, ensuring that as AI evolves, it does so with the patient’s voice at the forefront.
Source: Noah Wire Services